Ibrutinib Relieves Chronic Graft-Versus-Host Disease Symptoms

The targeted cancer therapy ibrutinib can effectively treat the symptoms of chronic graft-versus-host disease, a common and serious complication of allogeneic stem cell transplants, findings from a small clinical trial show.

Cancer Currents: An NCI Cancer Research Blog